

ASX Release

Anatara Investor Presentation

BRISBANE & MELBOURNE, 23rd August 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Investor Briefing, yesterday evening, in Melbourne.

A copy of the presentation is attached.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Twilight Investor Briefing August 2019



Advancing gastrointestinal health

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Key Investor Message

More than ever, the world is looking for safe and effective solutions to gut health.

The Anataro team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.



Corporate Fast Facts



ASX ticker code

ANR

Share Price

\$0.24*

Market Capitalisation

\$11.86 million*

Ordinary Shares

49,413,236

Options

2,571,000

Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

Management:

Steve Lydeamore, CEO

Dr Tracey Brown, CSO

Dr Michael West, COO

Product Development

Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Laureate Prof Nick Talley

Prof Jane Andrews

Prof Barry Campbell

Assoc Prof Simon Keely

Investment highlights: multiple shots on goal

Human health asset, GaRP:

- Aimed at restoring and maintaining **gut health** with excellent (pre-clinical) data to date
- **Animal study** results and **human clinical study** initiation anticipated late 2019
- Targeting **partnering** discussions in mid 2020

Animal health asset, Detach[®]:

- Asset developed for control of scour in piglets
- Well positioned in meat production market which is in need of non-antibiotic solutions
- Anantara currently targeting international animal health partner(s) to license and commercialise Detach[®]

Need to combat antimicrobial resistance

“Antimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.”

Dr Tedros Ghebreyesus, Director-General, World Health Organisation (WHO) 2019

70% of bacteria globally has developed some level of resistance to antibiotics¹

10 million: the number of people who could die every year due to AMR by 2050²

70% of antibiotics are used for food animal production³

>70% US consumers believe antibiotic-free meat benefits their own health⁴

Detach[®] can help

Detach[®] increases survivability and provides health benefits to pre-weaning piglets

- 15-20%⁵ of piglets born will die before weaning due to health issues including **scour**
- Orally administered, non-antibiotic product for the **control of scour** in piglets
- **Natural product** extracted from pineapple stems
- Unlike antibiotics and zinc oxide, Detach[®] **is unlikely to contribute to antimicrobial resistance**

Detach[®] Next Steps


- Secure international animal health partner(s)
 - **6-12 month timeframe**
 - regulatory approval of Detach[®] in key **overseas markets**
 - opportunity to fast track registration in SE Asia
 - develop **new formulations** and administration methods for Detach[®] to expand utility
 - develop Detach[®] for **other livestock species**, such as poultry





From animals to humans

No guts, no glory: why microbiome is so hot right now!



*Nature*⁷ says

According to *Nature*, **\$1.7 billion** has been spent on microbiome research in the last 10 years

A huge market

The global market for human microbiome-based drugs and diagnostics should reach a market size of nearly **\$9.9 billion by 2024***

Our place in the microbiome treatment landscape

Identifying a specific bacterial strain, or group of strains, that is delivered alive to the patient's gut



Drugs that specifically target the bacteria that cause disease while leaving the rest of the gut microbiome intact



ANATARA
LIFESCIENCES



C3J Therapeutics



SECOND GENOME

Fecal microbiota treatment (FMT)



Bacteriophages



BiomX

CRISPR/Cas9




Engineering bacteria to become drug factories directly within the human gut


Anaeropharma Science



ANATARA LIFESCIENCES

Burgeoning microbiome market: our first targets






*IBS is the **most commonly diagnosed gastrointestinal condition** and a significant cost burden on health care⁸*

IBS in a minute

11%

IBS affects around 11% of the global population⁹



It costs around **\$21billion** or more annually in direct medical costs and absenteeism¹⁰



Patients have a **poor quality of life** and **use healthcare system more than other patients**




IBS is a functional disorder, requiring **management of symptoms** such as **pain, bloating and alternating constipation and diarrhoea**



50% of patients turn to dietary supplements and complementary medicines¹¹

Profound impact on patients

A middle-aged man with grey hair is sitting on a light-colored sofa. He is wearing a red t-shirt and blue jeans. He is holding his stomach with both hands, looking down with a pained expression. The background shows a window with sheer curtains and several pillows on the sofa.

*"Imagine a day where you fell ill from having eaten too much, then imagine that day lasts **months at a time.**"*

Australian IBS patient¹²

IBS - one of the most burdensome chronic ailments reported by patients¹³



Individuals with IBS restrict their activities an average of

73 DAYS a year¹³



45% of IBS-D* patients agreed with the statement

"I'm willing to try anything to help manage my IBS"¹⁴



Patients reported they would give up **25%** of their remaining life (approx. 15 years)¹⁴



14% said they would risk a **1/1000 chance of death** to live symptom-free¹⁴

* IBS-D = Irritable Bowel Disease - Diarrhoea Predominant

USA gastrointestinal health market

US \$8b

USA digestive remedies and GI supplement sales



8/10

Adults suffer annually
from a digestive issue¹⁵



US\$5b

OTC** digestive remedies 2018¹⁵



US\$3b

GI* supplement sales 2018¹⁶



↑ 11.9%

OTC** digestive remedies
over the past 5 years¹⁵

* GI = Gastrointestinal

** OTC = over-the-counter

Global consumer health market opportunity

US \$5.7b

Global probiotic supplement sales¹⁷

Probiotic supplements



Align® (P&G) sales
(U.S.) 2018:
US\$171.9m¹⁷

Other GI supplements



Iberogast® (Bayer) sales
(Germany) 2018:
US\$145m¹⁷


OTC digestive supplements




Buscopan® (Sanofi) sales
(Global) 2018:
US\$220m¹⁸

(OTC only, excludes prescription sales)

3 primary underlying factors of IBS and IBD



How are these addressed?




***G**astrointestinal **ReP**rogramming (**GaRP**) dietary supplement

Changing the game for IBS

GaRP dietary supplement

- Regenerative, multi-component dietary supplement
 - Dual targeted formulation (small intestine and colon)
- Positioned as either an adjunct to existing therapies, or a sole therapy for IBS
- Designed to address 3 primary underlying factors associated with gastrointestinal disorders such as IBS and IBD
 - Strong pre-clinical evidence




Assumption or fact?

Anatara's Approach: evidence-based complementary medicine

- Most complementary medicines are listed, **not registered medicines**
- No requirement for own safety or efficacy studies for listed medicines
- **Anatara's approach is to develop its own evidence for safety and efficacy**
 - Pre-clinical *in vitro* models were used to determine likely impact on efficacy for each ingredient
 - Both *in vivo* animal models and a human clinical study will be used to demonstrate formulation safety and efficacy



Grounded in scientific evidence



Successful Proof of Concept Studies (February 2019)
Demonstrated using industry-standard *in vitro* gut models

Next steps: human trial

- **Pre-clinical animal studies** are currently underway where GaRP is being evaluated in a model representative of IBD
 - Data expected Q4 2019
- Pre-trial activities for a **human clinical study** in IBS patients have commenced, with a view to study initiation late 2019
- **Partnering discussions** to commence upon completion of pre-clinical animal studies **Q4 2019**
- View to a **partnering deal** by **mid 2020**



Bringing science to supplements

- **Evidence-based** breakthrough product for IBS and IBD
 - Triple-targeted therapeutic approach
 - **anti-adhesion; anti-inflammatory; mucosal regeneration**
 - Components delivered to where they can be most effective
- Fewer or lower regulatory requirements than pharmaceuticals¹⁹
 - **Lower development cost**
 - **Lower development risk**
 - **Faster time to market**
- **Swift timeframe to partnering milestone**





Contact Anatará Lifesciences Ltd

Steven Lydeamore, CEO

+61 438 027 172

slydeamore@anatará.com

www.anataralifesciences.com

@AnataráANR



anatará-lifesciences-ltd

